Angiotensin II Type 1 Receptor Autoantibody (AT1-AA)-Mediated Pregnancy Hypertension

American Journal of Reproductive Immunology

Volumn 69, Issue 4, 2013, Pages 413-418

  Herse, Florian ^a   Lamarca, Babbette ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II type 1 receptor; Autoantibodies; Preeclampsia; Pregnancy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR AUTOANTIBODY; AUTOANTIBODY; CANDESARTAN; CD135 ANTIGEN; IMIDAPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P22; PROTEIN P47; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; FEMALE; HEART MUSCLE CELL; HUMAN; MATERNAL HYPERTENSION; NONHUMAN; PATHOGENESIS; PLACENTA PERFUSION; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; UTERINE ARTERY;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; ENDOTHELIN-1; ENZYME ACTIVATION; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NADPH OXIDASE; NF-KAPPA B; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, CELL SURFACE; THROMBOPLASTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84875054513     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12072     Document Type: Review

References (59)

1. McLachlan SM, Rapoport B: Thyrotropin blocking autoantibodies and thyroid stimulating autoantibodies: insight into the pendulum from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2012; [Epub ahead of print].
2. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, Muscara M, Vignati G, Stramba-Badiale M, Catelli L, Lojacono A, Cavazzana I, Ghirardello A, Vescovi F, Gambari PF, Doria A, Meroni PL, Tincani A: Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832-1835.
3. Out HJ, Bruinse HW, Christiaens GC, van Vliet M, de Groot PG, Nieuwenhuis HK, Derksen RH: A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167:26-32.
4. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
5. ACOG practice bulletin: Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159-167.
6. Roberts JM, Pearson G, Cutler J, Lindheimer M: Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003; 41:437-445.
7. Barker DJ: Fetal origins of cardiovascular disease. Ann Med 1999; 31(Suppl 1):3-6.
8. Barker DJ: Intrauterine programming of coronary heart disease and stroke. Acta Paediatr Suppl 1997; 423:178-182, discussion 183.
9. Wolf G, Wenzel U, Stahl RA, Huneke B: Hypertensive disorders in pregnancy. Med Klin (Munich) 2001; 96:78-86.
10. Roberts JM, Cooper DW: Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357:53-56.
11. Li C, Ansari R, Yu Z, Shah D: Definitive molecular evidence of renin-angiotensin system in human uterine decidual cells. Hypertension 2000; 36:159-164.
12. Shah DM: The role of RAS in the pathogenesis of preeclampsia. Curr Hypertens Rep 2006; 8:144-152.
13. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H: Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005; 46:1275-1279.
14. Roberts JM: Gammill HS: Preeclampsia: recent insights. Hypertension 2005; 46:1243-1249.
15. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, Sjogren KG, Hjalmarson A, Muller-Esterl W, Hoebeke J: Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18:945-953.
16. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
17. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, Matucci-Cerinic M, Czirjak L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70:530-536.
18. Ingelfinger JR: Agonistic autoantibodies and rejection of renal allografts. N Engl J Med 2005; 352:617-619.
19. York MR: Novel insights on the role of the innate immune system in systemic sclerosis. Expert Rev Clin Immunol 2011; 7:481-489.
20. Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH: Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart 2011; 97:479-484.
21. Daikha-Dahmane F, Levy-Beff E, Jugie M, Lenclen R: Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists. Pediatr Nephrol 2006; 21:729-732.
22. Boix E, Zapater P, Pico A, Moreno O: Teratogenicity with angiotensin II receptor antagonists in pregnancy. J Endocrinol Invest 2005; 28:1029-1031.
23. Vendemmia M, Garcia-Meric P, Rizzotti A, Boubred F, Lacroze V, Liprandi A, Simeoni U: Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor-antagonists. J Matern Fetal Neonatal Med 2005; 18:137-140.
24. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC: AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382-2387.
25. Lindheimer MD, Umans JG: Explaining and predicting preeclampsia. N Engl J Med 2006; 355:1056-1058.
26. Xia Y, Wen H, Bobst S, Day MC, Kellems RE: Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 2003; 10:82-93.
27. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y: Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007; 100:88-95.
28. Xia Y, Ramin SM, Kellems RE: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007; 50:269-275.
29. Many A, Hubel CA, Fisher SJ, Roberts JM, Zhou Y: Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 2000; 156:321-331.
30. Sikkema JM, van Rijn BB, Franx A, Bruinse HW, de Roos R, Stroes ES, van Faassen EE: Placental superoxide is increased in pre-eclampsia. Placenta 2001; 22:304-308.
31. Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, Kaufmann P: Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003; 24:181-190.
32. Redman CW, Sargent IL: Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 2003; 24(Suppl A):S21-S27.
33. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC: AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003; 107:1632-1639.
34. Wang W, Irani RA, Zhang Y, Ramin SM, Blackwell SC, Tao L, Kellems RE, Xia Y: Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012; 60:712-721.
35. Hering L, Herse F, Verlohren S, Park JK, Wellner M, Qadri F, Pijnenborg R, Staff AC, Huppertz B, Muller DN, Luft FC, Dechend R: Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. Hypertension 2008; 51:554-559.
36. Derzsy Z, Prohaszka Z, Rigo J Jr: Fust G, Molvarec A: Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47:1500-1506.
37. Lim R, Lappas M: Decreased expression of complement 3a receptor (C3aR) in human placentas from severe preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 2012; 165:194-198.
38. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 2010; 121:436-444.
39. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124:940-950.
40. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
41. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, Markovic N, Thadhani R, Luft FC, Dechend R: Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007; 49:612-617.
42. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T: Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006; 91:2424-2427.
43. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010; 55:386-393.
44. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R: Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990; 163:460-465.
45. Roberts JM, Lain KY: Recent Insights into the pathogenesis of pre-eclampsia. Placenta 2002; 23:359-372.
46. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA, Granger JP: Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001; 37:1191-1195.
47. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP: Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 2005; 46:1022-1025.
48. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP: Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension 2008; 52:1168-1172.
49. LaMarca B, Wallace K, Herse F, Wallukat G, Martin Jr JN, Weimer A, Dechend R: Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 2011; 57:865-871.
50. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN: Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005; 45:742-746.
51. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin Jr JN, Ryan MJ, Dechend R: Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009; 54:905-909.
52. Parrish MR, Ryan MJ, Glover P, Brewer J, Ray L, Dechend R, Martin Jr JN, Lamarca BB: Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gend Med 2011; 8:184-188.
53. Parrish MR, Murphy SR, Rutland S, Wallace K, Wenzel K, Wallukat G, Keiser S, Ray LF, Dechend R, Martin JN, Granger JP, LaMarca B: The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens 2010; 23:911-916.
54. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y: Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51:1010-1019.
55. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y: Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14:855-862.
56. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC: A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682-2689.
57. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H, Brewer J, Roberts L, Hubel CA, Herse F, Hering L, Qadri F, Lindschau C, Wallukat G, Pijnenborg R, Heidecke H, Riemekasten G, Luft FC, Muller DN, Lamarca B, Dechend R: Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58:77-84.
58. Jensen F, Wallukat G, Herse F, Budner O, El-Mousleh T, Costa SD, Dechend R, Zenclussen AC: CD19 + CD5 + cells as indicators of preeclampsia. Hypertension 2012; 59:861-868.
59. Novotny SR, Wallace K, Heath J, Moseley J, Dhillon P, Weimer A, Wallukat G, Herse F, Wenzel K, Martin JN Jr: Dechend R, Lamarca B: Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4 + T lymphocytes from placental ischemic rats. Am J Physiol Regul Integr Comp Physiol 2012; 302:R1197-R1201.